Literature DB >> 36211203

Prevalence and clinical associations with primary hypogonadism in male systemic sclerosis.

Sapol Thepwiwatjit1, Suranut Charoensri1, Wichien Sirithanaphol2, Ajanee Mahakkanukrauh1, Siraphop Suwannaroj1, Chingching Foocharoen1.   

Abstract

Background: Systemic sclerosis may affect male and female fertility. Premature ovarian failure has been reported in female systemic sclerosis patients, but the effects on male fertility in systemic sclerosis have not been studied.
Objectives: We aimed to determine the prevalence and clinical associations with primary hypogonadism among male systemic sclerosis patients.
Methods: This was a cross-sectional pilot study, including 30 adult male systemic sclerosis patients attending the Scleroderma Clinic, Khon Kaen University. Testosterone deficiency symptoms were assessed using the Aging Males' Symptoms Rating Scale, urological examination, and blood testing (for total testosterone, free testosterone, follicle-stimulating hormone, and luteinizing hormone). We excluded patients with congenital hypogonadism and any acquired disorders of the testes and genitalia. The definition of primary hypogonadism was based on the International Society for the Study of the Aging Male 2015 diagnostic criteria for hypogonadism.
Results: Seven patients met the definition of primary hypogonadism-a prevalence of 23.3% (95% confidence interval: 9.9-42.3). The respective mean age and mean systemic sclerosis duration was 59.4 ± 11.9 and 5.5 ± 4.7 years. Older age at onset, high triglyceride level, and older age starting corticosteroid treatment were significantly associated with primary hypogonadism (p = 0.02, 0.02, and 0.03, respectively). Systemic sclerosis subset, disease severity, and immunosuppressant use were not associated with primary hypogonadism among Thai male systemic sclerosis patients.
Conclusion: Around one-quarter of male systemic sclerosis patients had primary hypogonadism. Elderly onset of systemic sclerosis, hypertriglyceridemia, and late corticosteroid treatment were risk factors for developing primary hypogonadism.
© The Author(s) 2022.

Entities:  

Keywords:  Systemic sclerosis; fertility; primary hypogonadism; scleroderma-related disorder; testosterone

Year:  2022        PMID: 36211203      PMCID: PMC9537708          DOI: 10.1177/23971983221112021

Source DB:  PubMed          Journal:  J Scleroderma Relat Disord        ISSN: 2397-1983


  44 in total

1.  Glucocorticoids inhibit gonadotropin-releasing hormone by acting directly at the hypothalamic level.

Authors:  A E Calogero; N Burrello; A M Bosboom; M R Garofalo; R F Weber; R D'Agata
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  The burden of depression in systemic sclerosis patients: a nationwide population-based study.

Authors:  Nicola L Bragazzi; Abdulla Watad; Alex Gizunterman; Dennis McGonagle; Hussein Mahagna; Doron Comaneshter; Howard Amital; Arnon D Cohen; Daniela Amital
Journal:  J Affect Disord       Date:  2018-09-21       Impact factor: 4.839

3.  Scleroderma in South Australia: epidemiological observations of possible pathogenic significance.

Authors:  P J Roberts-Thomson; M Jones; P Hakendorf; A A Kencana Dharmapatni; J G Walker; J G MacFarlane; M D Smith; M J Ahern
Journal:  Intern Med J       Date:  2001 May-Jun       Impact factor: 2.048

4.  Clinical features of 405 Japanese patients with systemic sclerosis.

Authors:  Atsushi Hashimoto; Hirahito Endo; Hirobumi Kondo; Shunsei Hirohata
Journal:  Mod Rheumatol       Date:  2011-08-28       Impact factor: 3.023

5.  Sexual dysfunction in patients with systemic sclerosis

Authors:  İsmail Uçar; Batuhan Turgay; Orhan Küçükşahin; Esma Özkan Uçar; Murat Turgay
Journal:  Turk J Med Sci       Date:  2018-12-12       Impact factor: 0.973

6.  Epidemiological study of patients with systemic sclerosis in Tokyo.

Authors:  T Tamaki; S Mori; K Takehara
Journal:  Arch Dermatol Res       Date:  1991       Impact factor: 3.017

7.  Systemic sclerosis in Iceland. A nationwide epidemiological study.

Authors:  A J Geirsson; K Steinsson; S Guthmundsson; V Sigurthsson
Journal:  Ann Rheum Dis       Date:  1994-08       Impact factor: 19.103

8.  The Aging Males' Symptoms scale (AMS) as outcome measure for treatment of androgen deficiency.

Authors:  Claudia Moore; Doris Huebler; Thomas Zimmermann; Lothar A J Heinemann; Farid Saad; Do Minh Thai
Journal:  Eur Urol       Date:  2004-07       Impact factor: 20.096

9.  Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research group.

Authors:  Chingching Foocharoen; Alan Tyndall; Eric Hachulla; Edoardo Rosato; Yannick Allanore; Dominique Farge-Bancel; Paola Caramaschi; Paolo Airó; Starovojtova M Nikolaevna; José António Pereira da Silva; Bojana Stamenkovic; Gabriela Riemekasten; Simona Rednic; Jean Sibilia; Piotr Wiland; Ingo Tarner; Vanessa Smith; Anna T Onken; Walid Ahmed Abdel Atty Mohamed; Oliver Distler; Jadranka Morović-Vergles; Andrea Himsel; Paloma Garcia de la Peña Lefebvre; Thomas Hügle; Ulrich A Walker
Journal:  Arthritis Res Ther       Date:  2012-02-20       Impact factor: 5.156

10.  Haemodynamic definitions and updated clinical classification of pulmonary hypertension.

Authors:  Gérald Simonneau; David Montani; David S Celermajer; Christopher P Denton; Michael A Gatzoulis; Michael Krowka; Paul G Williams; Rogerio Souza
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.